MS drug shows promise in trials

An experimental drug to treat multiple sclerosis is showing promise in clinical trials.

Researchers at the Cleveland Clinic have been studying the medication.

It’s on track to become just the third oral drug available to MS patients, and potentially the safest and most effective.

BG12 is an anti-inflammatory that works by protecting nerves against injury.

Taking it twice a day reduced the number of new or newly growing brain lesions by up to 99%.

The drug also reduced the number of MS relapses by about 50%.